ÍøºìºÚÁÏ

Skip to main content
(352) 265-7337

Michael J Haller, MD : Research

Pediatric Endocrinologist (Child Hormone Specialist)

Photo of Michael J Haller
(352) 265-7337 MyUFÍøºìºÚÁÏ

Research at a glance

Top areas of exploration

  • Diabetes Mellitus, Type 1 , 65 publications
  • Insulin , 15 publications
  • Blood Glucose , 14 publications
  • Glycated Hemoglobin , 13 publications

Research activity

145 publications

3,743 citations

Why is this important?

Focus

Dr. Haller's research focuses on predicting, preventing, and ultimately reversing type 1 diabetes through his participation in numerous clinical trials utilizing immunotherapies. Dr. Haller serves as the Principal Investigator for the University of Florida TrialNet Clinical Center, Chair of the TEDDY Clinical Implementation Committee, and PI of the UF/Stanford ECHO Collaborative. Dr. Haller also leads and participates in technology studies seeking to improve the lives of people living with diabetes through the use of pumps, continuous glucose monitors, and systems that automate insulin delivery.

Active clinical trials

PROTECT Extension Study

The purpose of this non-interventional extension study is to continue to collect long-term safety and other clinical data for an additional 42 months in participants who completed the PROTECT study.

Investigator
Michael J Haller
Status
Accepting Candidates
Ages
9 Years - 19 Years
Sexes
All

My publications

145 publications

2025

Project ECHO Diabetes Trial Improves Outcomes for Medically Underserved People

Diabetes Care

2025

Project Extension for Community ÍøºìºÚÁÏcare Outcomes Intervention Evaluations: A Scoping Review of Research Methods.

The Journal of continuing education in the health professions

•

2025

Serological markers of exocrine pancreatic function are differentially informative for distinguishing individuals progressing to type 1 diabetes

BMJ Open Diabetes Research & Care

2024

Confronting ÍøºìºÚÁÏ Misinformation Surrounding COVID-19 Vaccines in the State of Florida

Journal of General Internal Medicine

2024

Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes

Diabetologia